Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBP-336 in obese individuals with knee osteoarthritis
2024-517264-27-00Phase 2Completed
- Sponsor
- KeyBioscience AG
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in obesity and knee osteoarthritis (OA) comparing KBP-336 with Placebo (2 arms). Primary endpoints: Proportional change from baseline in body weight at Day 183 and Change from baseline in WOMAC pain scale at Day 183. Started Dec 2024; status: completed.
02
Drugs
KBP-336
03
Conditions
obesityknee osteoarthritis (OA)
Beyond the preview
Go deeper on 2024-517264-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517264-27-00.